Introgen Therapeutics (INGN) Returns Positive Results in Phase III Trials on ADVEXIN(R)
Introgen Therapeutics, Inc. (NASDAQ: INGN) today announced that ADVEXIN(R) significantly increased survival in end-stage head and neck cancer patients with prospectively identified p53 favorable profiles (7.2 vs. 2.7 months; p less than 0.0001). In the intent-to-treat population, including patients with p53 favorable and unfavorable p53 profiles, ADVEXIN and methotrexate had similar overall survival while ADVEXIN had a superior safety profile. ADVEXIN is designed to restore p53 tumor suppression blocked in the majority of tumors. The compound works differently than other cancer therapies by restoring the effectiveness of p53 proteins to trigger natural tumor suppression mechanisms in cancer, without harming normal cells.
Introgen Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted molecular therapies for the treatment of cancer and other diseases.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
